Compare · ABBV vs MLTX
ABBV vs MLTX
Side-by-side comparison of AbbVie Inc. (ABBV) and MoonLake Immunotherapeutics (MLTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and MLTX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $449.63B, about 310.4x MLTX ($1.45B).
- Over the past year, ABBV is up 37.7% and MLTX is down 63.3% - ABBV leads by 101.0 points.
- ABBV has been more active in the news (13 items in the past 4 weeks vs 3 for MLTX).
- Both have 25 recent analyst ratings on file.
- Company
- AbbVie Inc.
- MoonLake Immunotherapeutics
- Price
- $254.52+0.06%
- $19.69+3.66%
- Market cap
- $449.63B
- $1.45B
- 1M return
- +14.38%
- +4.29%
- 1Y return
- +37.70%
- -63.26%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- 2020
- News (4w)
- 13
- 3
- Recent ratings
- 25
- 25
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
Latest ABBV
- Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients
- SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- AbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
- SEC Form 4 filed by Director Rapp Edward J
- SEC Form 4 filed by Director Quaggin Susan E
- A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity
- AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- FDA Approval for SKYRIZI issued to ABBVIE INC
Latest MLTX
- Chief Executive Officer Santos Da Silva Jorge sold $2,046,205 worth of Class A ordinary shares (102,225 units at $20.02) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 2,774,893 units (SEC Form 4)
- Chief Executive Officer Santos Da Silva Jorge sold $956,933 worth of Class A ordinary shares (47,775 units at $20.03) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 2,877,118 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13D/A filed by MoonLake Immunotherapeutics
- MoonLake Immunotherapeutics filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form 424B5 filed by MoonLake Immunotherapeutics
- MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering
- Chief Financial Officer Bodenstedt Matthias sold $862,205 worth of Class A ordinary shares (39,120 units at $22.04) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 1,115,435 units (SEC Form 4)
- MoonLake Immunotherapeutics Announces Proposed Public Offering
- SEC Form 424B5 filed by MoonLake Immunotherapeutics
- SEC Form 4 filed by Director Bvf Partners L P/Il